VKTXHealthcare · BiotechnologyThe 21 Wall Street analysts covering Viking Therapeutics, Inc. hold a median 12-month price target of $95 — +289.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 24 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Viking Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (73): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (19): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VKTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +289.7% from it.
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Oct 2026 | Canaccord Genuity | Maintains | Buy | $114 → $106 |
| 15 Oct 2026 | UBS | Initiates | Buy | $94 |
| 7 Oct 2026 | Truist Securities | Maintains | Buy | $87 → $85 |
| 7 Oct 2026 | Truist Securities | Maintains | Buy | — |
| 23 Sept 2026 | Truist Securities | Maintains | Buy | — |
| 23 Sept 2026 | Truist Securities | Maintains | Buy | $83 → $87 |
| 11 Aug 2026 | JP Morgan | Maintains | Overweight | $75 → $65 |
| 11 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | $107 → $114 |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 28 May 2026 | Lake Street | Initiates | Buy | $89 |
| 28 May 2026 | Lake Street | Initiates | Buy | — |
| 1 May 2026 | BTIG | Reiterates | Buy | — |
| 30 Apr 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 23 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 29 Oct 2025 | Canaccord Genuity | Initiates | Buy | — |
| 24 Oct 2025 | JP Morgan | Maintains | Overweight | — |
| 23 Oct 2025 | Morgan Stanley | Maintains | Overweight | — |
| 29 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VKTX appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, Viking Therapeutics, Inc. returned −28.1% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 13% of US stocks
Cheaper than 82% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 15% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Viking Therapeutics, Inc. has a market value of $3.1B and an enterprise value of $2.3B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$534.8M.
Diluted earnings per share, trailing twelve months: $−4.66.
Free cash flow in the twelve months to 30 June 2026: −$418.4M.
Trailing P/E: −7.6×; forward P/E: −5.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Viking Therapeutics, Inc. employs 65 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Viking Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Viking Therapeutics is scheduled to report third-quarter results on October 28, 2026. The excerpt says its shares fell 41, but does not specify the unit or period.
Why it matters — The report date and the article’s stated focus on Viking’s oral obesity strategy are points of interest for VKTX watchers.
Viking Therapeutics (VKTX) finished the recent trading session at $24.42, down 5.48% from the prior day's close. The headline says the stock fell more than the broader market.
Why it matters — The session decline and its relative performance provide VKTX watchers with a snapshot of the stock's recent trading.
Viking Therapeutics (VKTX) closed at $25.76, down 2.35% from the preceding trading day. The headline says the stock fell more steeply than the broader market.
Why it matters — VKTX watchers may note the reported daily decline and its relative performance versus the broader market.
Zacks compared Viking Therapeutics with Novo Nordisk, saying VKTX’s late-stage obesity drug and weight-maintenance data could offer greater upside, alongside higher clinical and commercial risks.
Why it matters — The comparison highlights VKTX’s potential and the elevated risks associated with its obesity-drug development and commercialization.
Viking Therapeutics announced it will report its third-quarter 2026 financial results after market close on October 28, 2026. The company also scheduled a conference call for 4:30 p.m. Eastern Time that day.
Why it matters — VKTX watchers can note the date and time when the company plans to release results and discuss them on a call.
The 21 Wall Street analysts covering Viking Therapeutics, Inc. have a median 12-month price target of $95, with estimates ranging from $38 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 21 analysts covering Viking Therapeutics, Inc., 19 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viking Therapeutics, Inc. 35 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, Viking Therapeutics, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (73 of 100).
No one can know that. What the data says: the median 12-month target from 21 analysts implies +289.7% from the last close, and Ticker Nerd's factor model ranks Viking Therapeutics, Inc. 35 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Viking Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VKTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $125 over the next 12 months.
Viking Therapeutics, Inc. returned -28.1% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders.
The most recent item we track (24/7 Wall Street, 25 Oct 2026): "Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28". Viking Therapeutics is scheduled to report third-quarter results on October 28, 2026. The excerpt says its shares fell 41, but does not specify the unit or period.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being studied in oral and injectable forms for obesity and other metabolic conditions, along with VK2809, a thyroid hormone receptor beta agonist being evaluated for metabolic liver disease. The company also works on VK0214 for X-linked adrenoleukodystrophy, VK5211 for recovery after hip fracture surgery, VK0612 for metabolic disorders and anemia, and VK3019, an amylin receptor agonist in early study. Based in San Diego, California, Viking Therapeutics is positioned as a research-focused drug developer addressing high-need areas across obesity, liver disease, rare disease, and other endocrine-related conditions.
CEO Dr. Brian Lian Ph.D. · 65 employees · United States · https://www.vikingtherapeutics.com
